• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

    5/28/25 5:51:00 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care
    Get the next $AORT alert in real time by email

    ATLANTA, May 28, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the closing of transactions related to previously announced, privately negotiated exchange agreements with certain holders (the "Holders") of its 4.250% Convertible Senior Notes due 2025 (the "Notes"). The closing transactions included the closing of an additional, privately negotiated agreement with a separate holder.

    (PRNewsfoto/Artivion, Inc.)

    Under the terms of the exchange agreements, the Holders exchanged an aggregate principal amount of approximately $99.54 million of Notes held by the Holders in exchange for an aggregate of 4,334,347 shares of the Company's common stock ("Shares"). In addition, pursuant to the exchange agreements, the Company made a cash payment of approximately $1.7 million to the Holders for accrued and unpaid interest on the exchanged Notes. Immediately following the closing of the transactions contemplated by the exchange agreements, approximately $0.46 million in aggregate principal amount of the Notes remained outstanding.

    "The closing of these transactions results in the effective retirement of our convertible notes and marks a significant milestone in strengthening our financial position. By nearly eliminating this outstanding debt, we are not only meaningfully reducing our leverage ratios but also substantially enhancing our balance sheet flexibility," said Pat Mackin, Chairman, President, and Chief Executive Officer.

    J. Wood Capital Advisors LLC acted as financial advisor to Artivion in connection with the exchange transactions.

    The Shares issued in the exchanges have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state or other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and such other jurisdictions. This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

    Forward-Looking Statements

    Statements made in this press release that look forward in time, including those relating to closing of the exchange transactions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made and are subject to a number of risks, uncertainties, estimates and assumptions that may cause actual results to differ materially from current expectations, including, but not limited to, the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2024, and our Form 10-Q for the quarter ended March 31, 2025. Artivion does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise.

    About Artivion, Inc.

    Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com.

    Contacts:

    Artivion



















    Gilmartin Group LLC

    Lance A. Berry  



















    Brian Johnston / Laine Morgan

    Executive Vice President &



















    Phone: 332-895-3222

    Chief Financial Officer



















    [email protected]

    Phone: 770-419-3355





















     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-announces-closing-of-transactions-to-exchange-99-5-million-in-principal-amount-of-its-4-250-convertible-notes-due-2025-for-common-stock-302467699.html

    SOURCE Artivion, Inc.

    Get the next $AORT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AORT

    DatePrice TargetRatingAnalyst
    6/17/2025$35.00Buy
    Canaccord Genuity
    10/23/2024$33.00Mkt Outperform
    JMP Securities
    9/27/2022$32.00 → $28.00Buy
    Lake Street
    8/8/2022$32.00Buy
    Lake Street
    3/3/2022$30.00Buy
    Stifel
    2/18/2022$39.00 → $30.00Buy
    Needham
    More analyst ratings

    $AORT
    SEC Filings

    See more
    • SEC Form 144 filed by Artivion Inc.

      144 - ARTIVION, INC. (0000784199) (Subject)

      6/17/25 4:02:51 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Artivion Inc.

      SD - ARTIVION, INC. (0000784199) (Filer)

      5/19/25 10:17:29 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - ARTIVION, INC. (0000784199) (Filer)

      5/16/25 2:32:34 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on Artivion with a new price target

      Canaccord Genuity initiated coverage of Artivion with a rating of Buy and set a new price target of $35.00

      6/17/25 7:48:51 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • JMP Securities initiated coverage on Artivion with a new price target

      JMP Securities initiated coverage of Artivion with a rating of Mkt Outperform and set a new price target of $33.00

      10/23/24 6:17:27 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Lake Street reiterated coverage on Artivion with a new price target

      Lake Street reiterated coverage of Artivion with a rating of Buy and set a new price target of $28.00 from $32.00 previously

      9/27/22 11:06:42 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Clinical & MD Affair Stanton Marshall S. sold $442,500 worth of shares (15,000 units at $29.50), decreasing direct ownership by 19% to 64,200 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      6/18/25 11:48:26 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SVP, Clinical & MD Affair Stanton Marshall S. sold $743,131 worth of shares (26,132 units at $28.44), decreasing direct ownership by 25% to 79,200 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      6/16/25 8:22:21 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SVP, General Counsel Holloway Jean F sold $253,692 worth of shares (8,748 units at $29.00), decreasing direct ownership by 5% to 178,510 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      5/27/25 5:29:35 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • May 23, 2023 - FDA Roundup: May 23, 2023

      For Immediate Release: May 23, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA and the Veterans Health Administration announced a new collaboration to jointly develop emergency preparedness and response tools and protocols intended to help increase medical product manufacturing capacity and flexibility, and improve resilie

      5/23/23 4:06:19 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Semedo Anthony B. bought $53,140 worth of shares (2,100 units at $25.30), increasing direct ownership by 4% to 35,659 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/5/25 4:01:01 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Artivion to Participate in Upcoming Investor Conferences

      ATLANTA, June 3, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investors conferences. Artivion's management team will present at the upcoming Truist Securities MedTech Conference on Tuesday, June 17, 2025, at the InterContinental Boston Hotel. The Company's presentation is scheduled to begin at 8:00 a.m. ET. A live webcast can be accessed through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be

      6/3/25 4:10:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

      ATLANTA, May 28, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the closing of transactions related to previously announced, privately negotiated exchange agreements with certain holders (the "Holders") of its 4.250% Convertible Senior Notes due 2025 (the "Notes"). The closing transactions included the closing of an additional, privately negotiated agreement with a separate holder. Under the terms of the exchange agreements, the Holders exchanged an aggregate principal amount of approxi

      5/28/25 5:51:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

      ATLANTA, May 14, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it entered into separate, privately negotiated exchange agreements with certain holders of its 4.250% Convertible Senior Notes due 2025 (the "Existing Convertible Notes"). Under the exchange agreements, the company will, subject to customary closing conditions, repurchase approximately $95 million principal amount of Existing Convertible Notes in exchange for a number of shares of the company's common stock to be determined based on the trading price of the common stock over a four trading day averaging period beginning on May 15, 20

      5/14/25 4:01:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Leadership Updates

    Live Leadership Updates

    See more
    • Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer

      Reaffirms Financial Guidance Provided on November 2, 2023 ATLANTA, Dec. 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease today announced the appointment of Lance A. Berry as the Company's Chief Financial Officer, effective as of December 4, 2023. In this role, Mr. Berry joins Artivion's executive leadership team and replaces Mr. D. Ashley Lee, who will retire at the end of the year after a successful and long tenure with the Company and a distinguished career in the medical device industry. Artivion also reaffirmed its full-year 2023 financial guidance that was provided on November 2, 2023.

      12/6/23 4:15:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Sequana Medical announces results of Special General Meeting of Shareholders

      PRESS RELEASEREGULATED INFORMATION26 June 2023, 06:00 pm CEST Dr. Kenneth Macleod appointed as non-executive director Ghent, Belgium – 26 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the Special General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST. The items on the agenda of the meeting included the appointment of Dr. Kenneth Macleod as non-executive director of the Company and the approval in accordance with Article 7:151 of the Belgian Companies and Asso

      6/26/23 12:00:00 PM ET
      $AORT
      $PHAR
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Elizabeth Hoff Joins Artivion Board of Directors

      ATLANTA, Sept. 29, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Elizabeth A. Hoff to its Board of Directors effective October 1, 2022. "We are excited to welcome Elizabeth to our Board of Directors," said Pat Mackin, Chairman, President, and Chief Executive Officer. "Elizabeth brings a wealth of knowledge in the medical device industry demonstrated by her tenure in the aortic space leading teams focused on the development and commercial launch of innovative healthca

      9/29/22 4:10:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Financials

    Live finance-specific insights

    See more
    • Artivion Reports First Quarter 2025 Financial Results

      First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basisNet loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 202430-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a 63% reduction in the major adverse event (MAE) rate compared with reference perf

      5/5/25 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth Quarter Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an increase of 4% on a GAAP basis and 3% on a non-GAAP constant currency basisAchieved revenue of $388.5 million for the full year of 2024 versus $354.0 million for the full year of 2023, an increase of 10% on a GAAP basis and 9% on a non-GAAP constant currency basisNet loss was $(16.5) million, or $(0.39) per fully diluted share and non-GAAP net income was $0.2 million, or $0.00 per fully diluted share in the fourth quarter of 2024. For the full year, net loss was $(13.4) million, compared to a net loss of $(30.7) million in the 2023 fiscal yearAdju

      2/24/25 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports Third Quarter 2024 Financial Results

      Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basisNet loss was ($2.3) million or ($0.05) per fully diluted share and non-GAAP net income was $5.0 million or $0.12 per fully diluted share in the third quarter of 2024Adjusted EBITDA increased 28% to $17.7 million in the third quarter of 2024 compared to $13.9 million in the third quarter of 2023Submitted first module of the pre-market approval application (PMA) for AMDS Hybrid Prosthesis with the U.S. Food and Drug AdministrationEnrollment completed in NEXUS TRIOMPHE clinical

      11/7/24 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Artivion Inc.

      SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

      11/8/24 10:29:29 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Artivion Inc.

      SC 13G - ARTIVION, INC. (0000784199) (Subject)

      3/11/24 5:45:25 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Artivion Inc. (Amendment)

      SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

      2/14/24 6:18:56 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care